The Vanguard Group, Inc.: Disclosure on Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a disclosure under Form 8.3 in relation to Avadel Pharmaceuticals plc. As specified by the Irish Takeover Panel Act, 1997, Vanguard's interests in securities of Avadel represent more than 1%. The filing date was November 21, 2025, covering activities through November 20, 2025. Vanguard owns or controls 5,564,981 ordinary shares of Avadel, accounting for 5.71% of such securities.

The disclosure details recent transactions, including the purchase of 2,777 shares and sale of 1,515 shares, both at a price of 22.94 USD per share. The document states there are no existing agreements or arrangements, formal or informal, relating to securities to incentivize dealing, nor any agreements regarding voting rights or future acquisitions.

Supplementary Form 8 is not attached, indicating no additional detailed disclosure of options or derivatives at this time.